Recipients of mRNA-1273 versus BNT162b2 had a lower risk for breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during predominance of the delta variant.
Pfizer Inc. plans to ask the US Food and Drug Administration to authorize its COVID-19 vaccine for emergency use in children aged 6 months to 4 years old.
The Moderna COVID-19 vaccine has received full approval for use in people 18 years and older, the US Food and Drug Administration announced.
COVID-19 vaccination is not associated with fecundability among couples trying to conceive.
The rate of thrombosis with thrombocytopenia syndrome (TTS) is higher after receipt of the Ad26.COV2.S vaccine than mRNA-based COVID-19 vaccines.
Receipt of three doses of an mRNA COVID-19 vaccine is associated with protection against delta and omicron compared with being unvaccinated and receipt of two doses.
Neutralization titers against the omicron variant are lower than those against the D614G variant following the primary two-dose series of the mRNA-1273 vaccine, but a booster dose of mRNA-1273 vaccine substantially increases them.
Receipt of a third COVID-19 mRNA vaccine dose is associated with increased vaccine effectiveness against COVID-19 hospitalization.
Moderna Inc. announced that it has launched a trial that will study the power of a redesigned booster shot — one that homes in on the highly contagious omicron variant.
Despite a low absolute risk, there is an increased relative risk for carditis associated with BNT162b2 (Pfizer-BioNTech) vaccination, particularly among men and adolescents.
